Exactly right! This is precisely what shorts and bashers keep hammering away at. No concrete (read marketable) acknowledgment about efficacy from anyone but management...a 1.5 million dollar salary and continuing requests (we just want to have the option but we probably won’t use it) for more compensation, and ever increasing bogeys none of which (not even HIV which by managements own admission should already have gotten through the FDA process already) seem to be anywhere near marketable. This company has very little cash in the bank. When you add the EUA “misrepresentation” this is what you have left if severe is anything other than conclusive to the FDA’s satisfaction:
1. Dilution (definitely)
2. A bunch of phase trials (mostly 2’s)
3. A disincentivized CEO
4. No published MOA paper. (So what if it is “political”)

Back the truck up? To what?...what matters here is SEVERE, SEVERE,SEVERE!!! This needs to be flawless. No excuses, no “typos” , no conference calls and above else no delays! This should be straightforward...who lived and who died. It would be great if a doc could quantify this ie. what out of a hundred vs placebo would force the FDA’s hand? The last question would be the realistic possibility of removing Nader Pourhassan...can it be done. He is not “sticking his neck out” with a 1.5 million dollar salary and even more compensation I assure you his “neck” is very well protected!...but not ours.